Semaglutide compounding fully restricted — final FDA enforcement.
503A pharmacies got 60-day notice. Compounded sema effectively dead in the US for personal-use scripts. Tirzepatide compounding still in safe-harbor.
3 min#semaglutide#compounded#fda#industry
The FDA's 18-month wind-down period for semaglutide ended this week. 503A pharmacies have 60 days to stop dispensing and 90 days to clear inventory.
Practical impact:
the telehealth platforms that route patients to compounders for semaglutide are now in the same legal posture as a prescriber writing for a non-compoundable drug. Most have already pivoted to tirzepatide, which remains in safe-harbor compounding territory pending the next shortage-list review (expected H1 2027).
For users:
sema at $189/mo from telehealth is effectively over. Options now are FDA-brand Wegovy at ~$1,300/mo (with manufacturer coupons sometimes lower), tirzepatide compounding (still legal), or the market.
We've updated How to source and the Semaglutide page cost section.
Share this